Stock Events

Stock Events

Barinthus Biotherapeutics. 

$0.63
11
+$0.04+5.93% Today

Statistics

Day High
0.65
Day Low
0.61
52W High
1.97
52W Low
0.54
Volume
723
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13MayExpected
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.62
-0.55
-0.47
-0.4
Expected EPS
-0.54
Actual EPS
-0.4

Financials

-408%Profit Margin
Unprofitable
2021
2022
2023
2024
29.94MRevenue
-122.15MNet Income

Analyst Ratings

4Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BRNS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other serious diseases, directly competing in the same therapeutic areas as Barinthus Biotherapeutics.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies for life-threatening diseases, overlapping with Barinthus Biotherapeutics' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of pharmaceutical products for the treatment of serious medical conditions, similar to Barinthus Biotherapeutics.
AMGEN
AMGN
Mkt Cap191.53B
Amgen is a global biotechnology company that develops innovative human therapeutics, with a product portfolio that competes with Barinthus Biotherapeutics in several key areas.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on neurology, autoimmune disorders, and rare diseases, competing with Barinthus Biotherapeutics in the biopharmaceutical sector.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.32B
Alnylam Pharmaceuticals works on RNAi therapeutics, a novel technology that competes with Barinthus Biotherapeutics' innovative approaches to drug development.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.51B
BioMarin Pharmaceutical focuses on rare genetic diseases, competing with Barinthus Biotherapeutics in targeting niche and underserved medical conditions.
Novartis
NVS
Mkt Cap293.34B
Novartis is a large pharmaceutical company with a broad range of products that compete across several of Barinthus Biotherapeutics' key strategic areas.
Pfizer
PFE
Mkt Cap156.77B
Pfizer is a global pharmaceutical corporation with a diverse portfolio, including areas that overlap with the therapeutic focus of Barinthus Biotherapeutics.

About

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Show more...
CEO
Mr. William James Enright MBA
Employees
105
Country
United Kingdom
ISIN
US91864C1071

Listings

F
DE
2AB.F
STU
DE
2AB.STU
MU
DE
2AB.MU
XNAS
US
BRNS

0 Comments

Share your thoughts

FAQ

What is Barinthus Biotherapeutics. stock price today?▼
The current price of BRNS is $0.63 USD — it has increased by +5.93% in the past 24 hours. Watch Barinthus Biotherapeutics. stock price performance more closely on the chart.
What is Barinthus Biotherapeutics. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Barinthus Biotherapeutics. stocks are traded under the ticker BRNS.
Is Barinthus Biotherapeutics. stock price growing?▼
BRNS stock has risen by +5.57% compared to the previous week, the month change is a -0.79% fall, over the last year Barinthus Biotherapeutics. has showed a -17.22% decrease.
What were Barinthus Biotherapeutics. earnings last quarter?▼
BRNS earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.54 USD resulting in a +25.93% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Barinthus Biotherapeutics. revenue for the last year?▼
Barinthus Biotherapeutics. revenue for the last year amounts to 29.94M USD.
What is Barinthus Biotherapeutics. net income for the last year?▼
BRNS net income for the last year is -122.15M USD.
How many employees does Barinthus Biotherapeutics. have?▼
As of April 22, 2026, the company has 105 employees.
In which sector is Barinthus Biotherapeutics. located?▼
Barinthus Biotherapeutics. operates in the Health & Wellness sector.
When did Barinthus Biotherapeutics. complete a stock split?▼
Barinthus Biotherapeutics. has not had any recent stock splits.
Where is Barinthus Biotherapeutics. headquartered?▼
Barinthus Biotherapeutics. is headquartered in Germantown, United Kingdom.